MARKET NEWS

Kymanox Announces First Executive Advisor: Fran DeGrazio
Priority Review Granted for the First Oral & First New SERD in 20 years to Treat Metastatic Breast Cancer
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership With Ginkgo Bioworks
VYNE Therapeutics Announces Results From Phase 2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells From TCR-CAR+ Induced Pluripotent Stem Cells
Lexaria Bioscience Developing Powerful Tech to Treat Hypertension

  FEATURED EDITORIAL

  COMPANY PROFILE

Enteris BioPharma Inc., a wholly owned subsidiary of SWK Holdings Corp. (Nasdaq: SWKH), is a fully integrated development and manufacturing organization offering innovative oral drug delivery solutions. Since its founding in 2013, Enteris has adapted its oral drug delivery technology to advance multiple internal and client programs into the clinic. More recently, Enteris has completed a renovation of its 32,000 square-foot GMP facility, including HPAPI containment and handling, in Boonton, New Jersey, enabling long-term partnerships for challenging solid oral drug product development from preclinical through commercial cGMP manufacturing. Click here for more.

  EXCLUSIVE ONLINE CONTENT

 

Saama Collaborates With Merck to Build Machine Learning-Powered Clinical Data Layer to Strengthen Clinical Development Capabilities

Saama Collaborates With Merck to Build Machine Learning-Powered Clinical Data Layer to Strengthen Clinical Development Capabilities

Saama Technologies, LLC recently announced a multi-year agreement with Merck to build and operationalize a new clinical data layer leveraging Saama’s Life Science Analytics Cloud (LSAC) to….

Catalent to Acquire Metrics Contract Services for 5 Million

Catalent to Acquire Metrics Contract Services for $475 Million

Catalent, Inc. recently announced it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with a facility in….

BD, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients With Treatments

BD, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients With Treatments

BD (Becton, Dickinson and Company) recently announced a collaboration agreement with Labcorp, a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize….

Valneva & Pfizer Initiate Phase 3 Study of Lyme Disease Vaccine Candidate

Valneva & Pfizer Initiate Phase 3 Study of Lyme Disease Vaccine Candidate

Valneva SE and Pfizer recently announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - Antibody-Based Drug Discovery at the Speed of Light

WHITEPAPER - Antibody-Based Drug Discovery at the Speed of Light

Capabilities and technology combine to provide First-to-Human antibody discovery, development and clinical manufacturing. Speed, scientific expertise and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics.

Download our whitepaper and learn …

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

The Proveris by Design™ process offers a formalized approach to product development, all the while automating in vitro testing, and streamlining troubleshooting. It is an indispensable tool for successfully developing nasal spray and inhalation drug products as well as critical …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 24 – Drug Delivery
August 31 – Injection Devices